1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,396 | 0,440 | 12:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Fr | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | 1 | HKEx | ||
| 07.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 31.07. | IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 17.07. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II/III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF IGG4-RELATED DISEASE | 2 | HKEx | ||
| 06.07. | IMMUNEONCO-B (01541): (REVISED) NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 03.07. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.07. | IMMUNEONCO-B (01541): ANNOUNCEMENT PURSUANT TO RULES 14A.36, 14A.39 AND 14A.46 OF THE LISTING RULES | - | HKEx | ||
| 24.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 17.06. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT | 1 | HKEx | ||
| 16.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 08.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 2 | HKEx | ||
| 08.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.05. | IMMUNEONCO-B (01541): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026 | 2 | HKEx | ||
| 22.05. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 19.05. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II RANDOMIZED AND PLACEBO-CONTROLLED TRIAL OF IMM0306 FOR THE TREATMENT ... | - | HKEx | ||
| 30.04. | IMMUNEONCO-B (01541): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 28, 2026 | - | HKEx | ||
| 30.04. | IMMUNEONCO-B (01541): NOTICE OF THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.04. | IMMUNEONCO-B (01541): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 ... | - | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 77,11 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,780 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| PRAXIS PRECISION MEDICINES | 375,91 | 0,00 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,59 | 0,00 % | This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday | ||
| ALUMIS | 25,500 | 0,00 % | Alumis Inc.: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements | - ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO - - Alumis remains on track to submit its New Drug Application... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,275 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 31,600 | -0,09 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| CLIMB BIO | 17,450 | +0,06 % | Climb Bio, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 121,47 | +0,05 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 29,565 | 0,00 % | Arcus Biosciences GAAP EPS of -$0.72 beats by $0.17, revenue of $41M | ||
| ERASCA | 18,280 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 6,210 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 14,530 | -0,10 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| SEPTERNA | 44,200 | 0,00 % | H.C. Wainwright raises Septerna stock price target to $60 on SEP-479 progress | ||
| COGENT BIOSCIENCES | 37,890 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,14 % bei einem Aktienkurs von 0,366 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.